How Marco Pharma International Preserves German Homeopathic Traditions in America 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
BERKELEY, Calif., Jan. 04, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 11, 2018 at 7:30 a.m. PT.
The live and replayed versions of the webcast will be available by visiting the “Investors” section of the Dynavax website at www.dynavax.com.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company's first commercial product, HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
Ryan Spencer
VP, Corporate Strategy & Communications
510.665.4618
[email protected]
